OLEMA PHARMACEUTICALS, INC. Payments of Stock Issuance Costs
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Payments of Stock Issuance Costs of $25.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-08-10
- OLEMA PHARMACEUTICALS, INC. payments of stock issuance costs for the quarter ending 2026-06-30 was $0.00.
- OLEMA PHARMACEUTICALS, INC. payments of stock issuance costs for the quarter ending 2026-03-31 was $25.00K.
- OLEMA PHARMACEUTICALS, INC. payments of stock issuance costs for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. payments of stock issuance costs for the quarter ending 2024-06-30 was $25.00K.
- OLEMA PHARMACEUTICALS, INC. payments of stock issuance costs for fiscal 2023 was $264.00K.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 3 month as first filed | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $25.00K 10-Q · filed 2026-08-10 | |||
| 2026-03-31 | $25.00K 10-Q · filed 2026-05-12 | ||||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $25.00K derived: sum of 2 quarters · filed 2025-11-10 | $166.00K 10-Q · filed 2025-11-10 | $215.00K derived: sum of 4 quarters · filed 2025-11-10 | |
| 2024-06-30 | $25.00K 10-Q · filed 2025-08-11 | $166.00K 10-Q · filed 2025-08-11 | $215.00K derived: sum of 3 quarters · filed 2025-08-11 | $455.00K derived: sum of 4 quarters · filed 2025-08-11 | |
| 2024-03-31 | $166.00K 10-Q · filed 2025-05-13 | $167.00K 10-Q · filed 2024-05-08 | $190.00K derived: sum of 2 quarters · filed 2025-05-13 | $430.00K derived: sum of 3 quarters · filed 2025-05-13 | |
| 2023-12-31 | $24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $264.00K derived: sum of 2 quarters · filed 2025-03-18 | $264.00K 10-K · filed 2025-03-18 | ||
| 2023-09-30 | $240.00K 10-Q · filed 2024-11-12 | $240.00K 10-Q · filed 2024-11-12 | |||
| 2020-09-30 | $889.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |